Pitt Shield

Characterization of the Targeting Accuracy of a Neuronavigation-Guided Transcranial FUS System In Vitro, In Vivo, and In Silico.

Authors: Xu L, Pacia CP, Gong Y, Hu Z, Chien CY, Yang L, Gach HM, Hao Y, Comron H, Huang J, Leuthardt EC, Chen H

Focused ultrasound (FUS)-enabled liquid biopsy (sonobiopsy) is an emerging technique for the noninvasive and spatiotemporally controlled diagnosis of brain cancer by inducing blood-brain barrier (BBB) disruption to release brain tumor-specific biomarkers into the blood circulation. The feasibility, safety, and efficacy of sonobiopsy were demonstrated in both small and large animal models using magnetic resonance-guided FUS devices. However, the high cost and complex operation of magnetic resonance-guided FUS devices limit the future broad application of sonobiopsy in the clinic. In this study, a neuronavigation-guided sonobiopsy device is developed and its targeting accuracy is characterized in vitro, in vivo, and in silico. The sonobiopsy device integrated a commercially available neuronavigation system (BrainSight) with a nimble, lightweight FUS transducer. Its targeting accuracy was characterized in vitro in a water tank using a hydrophone. The performance of the device in BBB disruption was verified in vivo using a pig model, and the targeting accuracy was quantified by measuring the offset between the target and the actual locations of BBB opening. The feasibility of the FUS device in targeting glioblastoma (GBM) tumors was evaluated in silico using numerical simulation by the k-Wave toolbox in glioblastoma patients. It was found that the targeting accuracy of the neuronavigation-guided sonobiopsy device was 1.7 ± 0.8 mm as measured in the water tank. The neuronavigation-guided FUS device successfully induced BBB disruption in pigs with a targeting accuracy of 3.3 ± 1.4 mm. The targeting accuracy of the FUS transducer at the GBM tumor was 5.5 ± 4.9 mm. Age, sex, and incident locations were found to be not correlated with the targeting accuracy in GBM patients. This study demonstrated that the developed neuronavigation-guided FUS device could target the brain with a high spatial targeting accuracy, paving the foundation for its application in the clinic.

Introduction

Purpose Sonobiopsy
Study Objective To develop a neuronavigation-guided focused ultrasound sonobiopsy device and characterize its targeting accuracy in vitro, in vivo, and in silico.
Animal model / Human subject pig, not specified, not specified, not specified
Disease model healthy
MRI or image guidance method Neuronavigation guidance using BrainSight (neuronavigation-guided FUS)
Targeted brain region(s) Tumor

Outcomes and Safety

Summary of Outcomes Neuronavigation-guided FUS enabled accurate targeting and BBB disruption for sonobiopsy in glioblastoma models.
Duration of biological effect not reported
Safety-related matter No adverse effects reported.

Brain Region

Ultrasound Parameters

Ultrasound instrument not reported
FUS Frequency not reported
FUS Intensity not reported
FUS Pressure not reported
FUS Mode not reported
Pulse duration not reported
Duration of a single FUS session not reported

We are open to feedback. If you see a mistake or have a suggestion, please contact us.

← Back to Search